Cargando…

Female Malignancies and Immunotherapy: What’s New?

Detalles Bibliográficos
Autores principales:	Pesce, Silvia, Vellone, Valerio Gaetano, Marcenaro, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600966/ https://www.ncbi.nlm.nih.gov/pubmed/33050485 http://dx.doi.org/10.3390/cancers12102909

Ejemplares similares

New Insights into Endometrial Cancer
por: Paleari, Laura, et al.
Publicado: (2021)

Immunotherapy in Thoracic Malignancies: New Treatment and New Hope
por: Melosky, Barbara
Publicado: (2022)

Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor
por: Pesce, Silvia, et al.
Publicado: (2016)

miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy
por: Pesce, Silvia, et al.
Publicado: (2020)

Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
por: Provinciali, Nicoletta, et al.
Publicado: (2022)

Uptake of CCR7 by KIR2DS4(+) NK Cells Is Induced upon Recognition of Certain HLA-C Alleles
por: Pesce, Silvia, et al.
Publicado: (2015)

NK Cell-Based Immunotherapy in Colorectal Cancer
por: Della Chiesa, Mariella, et al.
Publicado: (2022)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

Advances in cancer immunotherapy for gastroenterological malignancy
por: Kono, Koji
Publicado: (2018)

TLR/NCR/KIR: Which One to Use and When?
por: Sivori, Simona, et al.
Publicado: (2014)

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
por: Pesce, Silvia, et al.
Publicado: (2020)

Features of Memory-Like and PD-1(+) Human NK Cell Subsets
por: Della Chiesa, Mariella, et al.
Publicado: (2016)

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands
por: Pesce, Silvia, et al.
Publicado: (2017)

Downregulation of HLA Class I Renders Inflammatory Neutrophils More Susceptible to NK Cell-Induced Apoptosis
por: Bernson, Elin, et al.
Publicado: (2019)

Editorial: Innate Anti-Tumor Immune Responses in Solid and Hematological Malignancies: From Basic Research to Clinical Applications
por: Chretien, Anne-Sophie, et al.
Publicado: (2022)

Alpha-Synuclein and Parkinson’s Disease Motor and Non-Motor Symptoms: What Is New?
por: Grigoletto, Jessica, et al.
Publicado: (2022)

Malignant bone tumours in children: What’s up?
por: Alves, Cristina
Publicado: (2021)

Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies
por: Barar, Jaleh, et al.
Publicado: (2015)

Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know
por: Russo, Luca, et al.
Publicado: (2021)

Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
por: Innao, Vanessa, et al.
Publicado: (2020)

New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression
por: Pesce, Silvia, et al.
Publicado: (2018)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Parasitology: What's new, what's unusual?
por: Parija, Subhash Chandra
Publicado: (2020)

Introducing the society for immunotherapy of cancer’s new journal: journal for immunoTherapy of cancer
por: Romero, Pedro J, et al.
Publicado: (2013)

Prevention of Human Papillomavirus-Related Malignancies of the Female Genital Tract
por: Koliopoulos, George, et al.
Publicado: (2011)

New Insights into Immunotherapy for Gynecological Cancer
por: Kobori, Takuro
Publicado: (2022)

What is the Meaning of Anaphase-Promoting Complex 7 in Malignant Neoplasms?
por: Chang, Weon-Young
Publicado: (2017)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer
por: Greppi, Marco, et al.
Publicado: (2019)

Diabetes update: What's new, what's interesting
por: T. Bloomgarden, Zachary
Publicado: (2022)

Commentary on Special Issue “Fetal Growth: What Is New in the Clinical Research?”
por: Cosmi, Erich, et al.
Publicado: (2022)

Allergen immunotherapy in asthma; what is new?
por: Passalacqua, Giovanni, et al.
Publicado: (2015)

What is the new normal?
por: Mash, Robert
Publicado: (2020)

Immunotherapy: A New Hope for Cancer Patients
por: Gupta, Shalini, et al.
Publicado: (2020)

Rituximab biosimilars open new horizons in immunotherapy
por: Jaeger, Ulrich
Publicado: (2017)

Allergen Immunotherapy: New Insights into an Old Treatment
por: Pitsios, Constantinos
Publicado: (2022)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

New Insight in Histamine Functions
por: Sgambellone, Silvia, et al.
Publicado: (2022)

The New T Cell Subset Opens a New Realm for Tumor Immunotherapy
por: Zhu, Huanjin, et al.
Publicado: (2022)

WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies
por: Suzuki, Mikito, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5s095hbk07gp68mk4nqt91rp41